Litcius/Paper detail

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination

Georg M. N. Behrens, Anne Cossmann, Metodi V. Stankov, Inga Nehlmeier, Amy Kempf, Markus Hoffmann, Stefan Pöhlmann

2021The Lancet32 citationsDOIOpen Access PDF

Topics & Concepts

HeterologousNeutralizationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Virology2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)VaccinationBiologyComputer scienceMedicineGeneticsVirusInfectious disease (medical specialty)GeneOutbreakDiseasePathologySARS-CoV-2 and COVID-19 ResearchHeparin-Induced Thrombocytopenia and ThrombosisRetinal and Optic Conditions
SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination | Litcius